Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Trastuzumab |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Trastuzumab
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Trastuzumab Emtansine (T-DM1) |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Trastuzumab Emtansine (T-DM1)
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Trastuzumab Deruxtecan |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Trastuzumab Deruxtecan
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Pertuzumab |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Pertuzumab
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Margetuximab |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Margetuximab
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Zanidatamab |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Zanidatamab
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Disitamab Vedotin |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Disitamab Vedotin
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Trastuzumab Duocarmazine |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Trastuzumab Duocarmazine
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
TrastuzumabTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
Trastuzumab Emtansine (T-DM1)Targeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
Trastuzumab DeruxtecanTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
PertuzumabTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
MargetuximabTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
ZanidatamabTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
Disitamab VedotinTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
Trastuzumab DuocarmazineTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|

